PSMA ADC - Progenics Pharmaceuticals

Drug Profile

PSMA ADC - Progenics Pharmaceuticals

Alternative Names: Monomethylauristatin E-antiPSMA monoclonal antibody conjugate; PSMA Antibody Drug Conjugate

Latest Information Update: 08 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PSMA Development Company
  • Developer Brown University; Progenics Pharmaceuticals; Rhode Island Hospital; University of Texas at Dallas
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glioblastoma; Prostate cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 08 Feb 2018 Discontinued - Phase-II for Glioblastoma, Prostate cancer (First-line therapy, Hormone refractory, Metastatic disease) and Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (IV) (Not listed on Progenics pipeline, February 2018)
  • 09 Mar 2017 Progenics Pharmaceuticals has patent protection for PSMA ADC in USA and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top